Organigram Global Inc. (OGI) stock

OGINasdaqPharmaceutical PreparationsFiscal year ends September 30

Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 40-F on Dec 16, 2025Score 4/30

$0.83−0.01 (-0.65%)

Close on Nov 13, 2026Market cap $111.41MP/E –Yield –

Organigram Global statistics

61 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: –
Last ex-dividend date: No dividends
Fundamentals through: Sep 30, 2025
Share price as of: –

Valuation ratiosIndustry

Market Cap: C$157.16M; C$230.07M
Enterprise Value: C$73.59M; C$177.58M
PS Ratio: 0.61; 1.09

Enterprise valuationIndustry

EV / Sales: 0.28; 0.85
EV / EBITDA: 27.51; –

Share statisticsIndustry

Shares Outstanding: 134M; 75M
Float: 92M; 74M
Shares Held by Insiders: 31.4%; 0.00%
Shares Held by Institutions: 5.67%; 9.34%

Short sellingIndustry

Short Interest: 5M; –
Short Interest Change: 10.2%; -1.74%
Days to Cover: 21.23; 7.10

Stock price statisticsIndustry

Price Change (1 Week): -5.48%; -5.60%
Price Change (1 Month): -11.1%; -16.4%
Price Change (3 Months): -32.4%; -39.3%
Price Change (6 Months): -22.6%; -37.6%
Price Change (YTD): -50.7%; -50.7%
Price Change (1 Year): -48.5%; -46.6%
Price Change (3 Years): -31.5%; -32.7%
Price Change (5 Years): -91.1%; -86.8%
Price Change (10 Years): -92.9%; -92.9%
Average Volume (10 Days): 942,460; –
Average Volume (20 Days): 597,256; –
Average Volume (90 Days): 782,671; –
Relative Volume: 0.52; 0.83
Relative Strength Index (14): 31.1; 36.7
Volatility (1 Year): 56.9%; 81.6%
Beta (5 Years): 1.51; 1.24

MarginsIndustry

Gross Margin: 34.8%; 40.5%
Operating Margin: -5.90%; -21.2%
Pretax Margin: -14.9%; -22.6%
EBITDA Margin: 1.03%; -18.5%
FCF Margin: -9.50%; -9.50%

Returns on capitalIndustry

Return on Capital Employed (ROCE): -3.51%; -18.8%

Financial positionIndustry

Current Ratio: 2.26; 2.54
Quick Ratio: 1.18; 1.46
Debt / EBITDA: 0.01; –
Net Debt / EBITDA: -31.24; –

GrowthIndustry

Revenue Growth (3Y CAGR): 44.0%; 9.34%
Revenue Growth (5Y CAGR): 83.6%; 20.0%

EfficiencyIndustry

Asset Turnover: 0.46; 0.46
Inventory Turnover: 1.65; 5.40
WACC: 12.7%; 11.3%

Income statement (TTM)Industry

Revenue: C$259.18M; C$28.86M
Gross Profit: C$90.22M; C$9.87M
Operating Income: -C$15.30M; -C$16.55M
Pretax Income: -C$38.53M; -C$13.72M
EBITDA: C$2.68M; -C$16.37M
EPS (Diluted): -0.19 CAD; -0.19 CAD

Balance sheetIndustry

Cash & Short-Term Investments: C$83.59M; C$27.83M
Total Debt: C$25.00K; C$207.49K
Net Cash (Debt): C$83.57M; C$27.83M
Net Cash Per Share: 0.62 CAD; 0.25 CAD
Working Capital: C$158.74M; C$25.22M

Cash flow (TTM)Industry

Operating Cash Flow: -C$7.59M; -C$8.69M
Capital Expenditures: -C$17.02M; -C$510.54K
Free Cash Flow: -C$24.61M; -C$11.52M
FCF Per Share: -0.18 CAD; -0.07 CAD

Dividends and yieldsIndustry

FCF Yield: -15.7%; -15.7%

Taxes and interestIndustry

Income Tax: -C$13.77M; C$0

Scores and fair valueIndustry

Altman Z-Score: -0.36; -0.97

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	OGI	S&P 500	Difference	OGI per year	S&P 500 per year
1 month	-9.8%	-3.0%	−6.8 pts
3 months	-34.2%	-2.8%	−31.5 pts
Year to date	-50.7%	+11.5%	−62.2 pts
1 year	-46.2%	+13.5%	−59.7 pts
3 years	-28.6%	+77.7%	−106.3 pts	-10.6%	+21.1%
5 years	-91.1%	+72.6%	−163.7 pts	-38.4%	+11.5%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

5M OGI shares were sold short on Oct 30, 2026, up 10.2% from the previous report. At recent volumes it would take 21.2 days to buy them back. Over the last 20 sessions, 59.9% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	5,310,997	+10.2%	250,136	21.2
Oct 15, 2026	4,817,403	+7.2%	413,606	11.7
Sep 30, 2026	4,494,043	-7.8%	557,535	8.1
Sep 15, 2026	4,872,766	-10.6%	514,052	9.5
Aug 31, 2026	5,450,037	+12.9%	567,112	9.6
Aug 14, 2026	4,829,265	-8.0%	2,893,406	1.7
Jul 31, 2026	5,248,686	-0.5%	237,233	22.1
Jul 15, 2026	5,274,602	+12.0%	466,679	11.3
Jun 30, 2026	4,709,925	-19.4%	647,652	7.3
Jun 15, 2026	5,843,858	+7.9%	483,630	12.1
May 29, 2026	5,417,218	+9.3%	574,974	9.4
May 15, 2026	4,957,608	+26.9%	936,136	5.3

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Organigram Global's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-4 reverse split on Dec 19, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is OGI.

Compare: OGI vs INCR · OGI vs CGC · OGI vs ACB · OGI vs VREOF · OGI vs LGND

Revenue growth77.8% · median 10.7%

Gross margin34.8% · median 35.9%

Operating margin-5.9% · median 1.3%

Company	Revenue	Growth
VREOF	$673.67M	+255.8%
CGC	C$308.32M	+10.7%
OGI	C$259.18M	+77.8%
LGND	$253.83M	+1.0%
INCR	–	–
ACB	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: September 30
Held by institutions: 5.7%
Auditor: PKF OConnor Davies, LLP
SEC CIK: 1620737

Advertisement
300 × 250

See a number that looks wrong?